experspadmin

Most Effective Outcome Measures for Assessing Treatment Response in Relapsed/Refractory Chronic Lymphocytic Leukemia
Oncology

Most Effective Outcome Measures for Assessing Treatment Response in Relapsed/Refractory Chronic Lymphocytic Leukemia

expert roundtables
By Bruce D. Cheson, MD, FACP, FAAAS, FASCO; Jennifer R. Brown, MD, PhD
Recommendations for the Use of Maintenance and Consolidation Therapy in Chronic Lymphocytic Leukemia
Oncology

Recommendations for the Use of Maintenance and Consolidation Therapy in Chronic Lymphocytic Leukemia

expert roundtables
By Bruce D. Cheson, MD, FACP, FAAAS, FASCO; Jennifer R. Brown, MD, PhD
Early Identification of Patients With At-Risk Chronic Lymphocytic Leukemia
Oncology

Early Identification of Patients With At-Risk Chronic Lymphocytic Leukemia

patient care perspectives
Understanding the Reasons for Chronic Lymphocytic Leukemia Therapy Discontinuation
Oncology

Understanding the Reasons for Chronic Lymphocytic Leukemia Therapy Discontinuation

patient care perspectives
By Jennifer R. Brown, MD, PhD
MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibition in Chronic Lymphocytic Leukemia
Oncology

MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibition in Chronic Lymphocytic Leukemia

clinical topic updates
By Jennifer R. Brown, MD, PhD
Load More